Thus, targeting this pathway could inhibit tumor growth and progression, suggesting that therapies combining CDK4/6 inhibitors with agents that modulate SMURF2 activity could enhance anti-cancer efficacy (13). The gene discussed is SMURF2; the disease is neoplasm.